Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism

Journal of Neuroscience Methods

Volumn 123, Issue 2, 2003, Pages 189-200

  Tillerson, Jennifer L ^a   Miller, Gary W ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Center for Neurodegenerative Disease   (United States)

Author keywords

Behavioral assessment; Mice; Motor impairment; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; D 1507; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE BRAIN LEVEL; DRUG EFFECT; IMMUNOREACTIVITY; MALE; MEASUREMENT; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; TASK PERFORMANCE;

EID: 0037445497     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0270(02)00360-6     Document Type: Article

References (49)

1. Ballermann M., Metz G.A., McKenna J.E., Klassen F., Whishaw I.Q. The pasta matrix reaching task: a simple test for measuring skilled reaching distance, direction, and dexterity in rats. J. Neurosci. Methods. 106:2001;39-45.
2. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155:1999;268-273.
3. Carafoli E. Intracellular calcium homeostasis. Annu. Rev. Biochem. 56:1987;395-433.
4. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
5. Colotla V.A., Flores E., Oscos A., Meneses A., Tapia R. Effects of MPTP on locomotor activity in mice. Neurotoxicol. Teratol. 12:1990;405-407.
6. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. New Engl. J. Med. 276:1967;374-379.
7. Edwards R.H. Neural degeneration and the transport of neurotransmitters. Ann. Neurol. 34:1993;638-645.
8. Fornai F., Battaglia G., Gesi M., Giorgi F.S., Orzi F., Nicoletti F., Ruggieri S. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res. 887:2000;110-117.
9. Fredriksson A., Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J. Neural Transm. Park. Dis. Dement. Sect. 7:1994;123-132.
10. Fredriksson A., Plaznik A., Sundstrom E., Jonsson G., Archer T. MPTP-induced hypoactivity in mice: reversal by L-dopa. Pharmacol. Toxicol. 67:1990;295-301.
11. Fredriksson A., Eriksson P., Archer T. MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J. Neural Transm. 104:1997;579-592.
12. Fuller R.W., Hemrick-Luecke S.K. Mechanisms of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry. 9:1985;687-690.
13. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69:1997;1322-1325.
14. Haber S.N., Ryoo H., Cox C., Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 362:1995;400-410.
15. Hasegawa E., Takeshige K., Oishi T., Murai Y., Minakami S. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1990;1049-1055.
16. Heikkila R.E., Sonsalla P.K. The MPTP-treated mouse as a model of parkinsonism: how good is it? Neurochem. Int. 20:1992;299S-303S.
17. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
18. Heikkila R.E., Sieber B.A., Manzino L., Sonsalla P.K. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol. Chem. Neuropathol. 10:1989;171-183.
19. Ho A., Blum M. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J. Neurosci. 18:1998;5614-5629.
20. Kass G.E., Wright J.M., Nicotera P., Orrenius S. The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. Arch. Biochem. Biophys. 260:1988;789-797.
21. Kitayama S., Wang J.B., Uhl G.R. Dopamine transporter mutants selectively enhance MPP+ transport. Synapse. 15:1993;58-62.
22. Kopin I.J., Markey S.P. MPTP toxicity: implications for research in Parkinson's disease. Annu. Rev. Neurosci. 11:1988;81-96.
23. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
24. Langston J.W., Irwin I., DeLanney L.E. The biotransformation of MPTP and disposition of MPP+: the effects of aging. Life Sci. 40:1987;749-754.
25. Melamed E., Rosenthal J., Cohen O., Uzzan A., Globus M. Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP. Neuropharmacology. 24:1985;923-925.
26. Melamed E., Rosenthal J., Globus M., Cohen O., Uzzan A. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Res. 342:1985;401-404.
27. Melamed E., Rosenthal J., Cohen O., Globus M., Uzzan A. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur. J. Pharmacol. 116:1985;179-181.
28. Miller G.W., Staley J.K., Heilman C.J., Perez J.T., Mash D.C., Rye D.B., Levey A.I. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41:1997;530-539.
29. Mitsumoto Y., Watanabe A., Mori A., Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248:1998;660-663.
30. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
31. Nicklas W.J., Youngster S.K., Kindt M.V., Heikkila R.E. MPTP, MPP+ and mitochondrial function. Life Sci. 40:1987;721-729.
32. Ogawa N., Hirose Y., Ohara S., Ono T., Watanabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50:1985;435-441.
33. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144.
34. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15:1995;3863-3875.
35. Ramsay R.R., Krueger M.J., Youngster S.K., Gluck M.R., Casida J.E., Singer T.P. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56:1991;1184-1190.
36. Rozas G., Lopez-Martin E., Guerra M.J., Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods. 83:1998;165-175.
37. Schallert T., Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimizing behavioral assessment of outcome. Emerich D.F., Dean R.L.I., Sanberg P.R. Central Nervous System Diseases. 2000;131-151 Humana Press, USA.
38. Schallert T., Whishaw I.Q., Ramirez V.D., Teitelbaum P. Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science. 199:1978;1461-1463.
39. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125:2001;109-125.
40. Snyder S.H., D'Amato R.J. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology. 36:1986;250-258.
41. Spooren W.P., Vassout A., Waldmeier P., Gentsch C. Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity. Eur. J. Pharmacol. 353:1998;1-4.
42. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405:1987;26-38.
43. Sundstrom E., Fredriksson A., Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res. 528:1990;181-188.
44. Tillerson J.L., Cohen A.D., Philhower J., Miller G.W., Zigmond M.J., Schallert T. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21:2001;4427-4435.
45. Vyas I., Heikkila R.E., Nicklas W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J. Neurochem. 46:1986;1501-1507.
46. Willis G.L., Donnan G.A. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res. 402:1987;269-274.
47. Willis G.L., Horne M.K., Donnan G.A. Amine accumulation, catecholamine depletion and motor impairment in Macaca fasicularis and the C-57 black mouse after MPTP administration. Prog. Neuropsychopharmacol. Biol. Psychiatry. 12:1988;469-482.
48. Zigmond M.J., Stricker E.M. Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int. Rev. Neurobiol. 31:1989;1-79.
49. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.